Translating Scientific Breakthroughs into Promise for Patients

From discovery through commercialization, all of us at Ardelyx are driven to advance targeted therapies where significant medical needs persist. We have developed a unique and innovative platform that has enabled the discovery of new biological mechanisms and pathways to create targeted, first-in-class, oral, small molecule therapies to meet these needs. Our lead candidate, tenapanor, is currently under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

With Integrity and Dedication, We Make a Difference for Patients

Join Us

We are… Passionate. Fearless. Dedicated. Inclusive!

Patients & Families

Translating scientific breakthroughs into promise for patients.

For Investors

Creating value from

Recent News

February 17, 2021

Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference

November 23, 2020

Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare...

November 10, 2020

Ardelyx to Present at the Jefferies Virtual London Healthcare Conference